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Age-speciﬁc biological and molecular proﬁling
distinguishes paediatric from adult acute myeloid
leukaemias
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Acute myeloid leukaemia (AML) affects children and adults of all ages. AML remains one of
the major causes of death in children with cancer and for children with AML relapse is the
most common cause of death. Here, by modelling AML in vivo we demonstrate that AML is
discriminated by the age of the cell of origin. Young cells give rise to myeloid, lymphoid or
mixed phenotype acute leukaemia, whereas adult cells give rise exclusively to AML, with a
shorter latency. Unlike adult, young AML cells do not remodel the bone marrow stroma.
Transcriptional analysis distinguishes young AML by the upregulation of immune pathways.
Analysis of human paediatric AML samples recapitulates a paediatric immune cell interaction
gene signature, highlighting two genes, RGS10 and FAM26F as prognostically signiﬁcant. This
work advances our understanding of paediatric AML biology, and provides murine models
that offer the potential for developing paediatric speciﬁc therapeutic strategies.
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The incidence of acute myeloid leukaemia (AML) increaseswith age, and in childhood accounts for 20% of all leu-kaemia. The current overall survival rate in children is only
60–75%, and thereafter falls progressively with age to 5–15% in
the elderly. Both children and adults die from a combination of
relapse (up to 35% and 99%, respectively) and treatment-related
mortality during both induction and consolidation therapy1,2.
AML is characterised by impaired myeloid differentiation
resulting in the accumulation of myeloid blasts in the bone
marrow (BM) and peripheral blood (PB). Seminal studies in adult
AML3 have led to the leukaemia stem cell (LSC) hypothesis,
which postulates that leukaemias are organised into cellular
hierarchies, mirroring normal haemopoiesis. LSCs have similar
properties to normal adult HSCs at the apex of the haemopoietic
hierarchy, which differentiate into bulk leukaemia cells. In the
majority of adult human AMLs, the LSC has been identiﬁed as
either the LSK or a more mature progenitor cell that has acquired
self-renewal4,5. Current therapies fail to eradicate leukaemic cells,
which are protected in the BM microenvironment, interact with
the surrounding cells, and cause disease relapse6,7.
There are major differences between paediatric and adult AML
relating to (i) the frequency of de novo AML versus secondary
AML subsequent to underlying myeloproliferative neoplasms
(MPN) or myelodysplastic syndromes (MDS) and (ii) cytogenetic
and molecular abnormalities8–10. In children, the vast majority of
patients present with de novo AML while in adults, a signiﬁcant
proportion of AML arises from an underlying MPN or MDS and
this characteristically increases with age. This can be explained by
the signiﬁcant differences in genetic landscapes of paediatric and
adult AML. Only 20% of paediatric patients have a normal kar-
yotype and the number of somatic mutations is lower than in
adult AML (5 per paediatric sample versus 10–13 per adult
sample). Paediatric AML has a higher frequency of cytogenetic
abnormalities compared to adult, with some occurring almost
exclusively in infants/children. Furthermore, the epigenetic
landscapes of paediatric and adult AML are vastly different with
respect to the incidence and type of mutations in epigenetic
modulators11. The recent TARGET AML initiative comprehen-
sively showed the similarities and differences in the mutational
proﬁle of >1000 AML patients across the age spectrum, demon-
strating DNA methylation and miRNA proﬁles can stratify pae-
diatric patients in terms of overall and progression-free survival,
calling for an update to address-speciﬁc vulnerabilities of pae-
diatric subtypes12. To progress our understanding of paediatric
AML, it is important to establish models of disease that recapi-
tulate features of the disease to develop age-speciﬁc therapies.
Aging features, such as decreased immune response, increased
myeloid lineage skewing, genomic instability, reduced regen-
erative capacity of stem cells, and positive selection of pre-
leukaemic clones driven by cell intrinsic and extrinsic factors, are
all thought to contribute to the high incidence of AML in older
adults1,13. This does not explain the occurrence of AML in
children. Neonatal HSCs are a cycling population compared to
the quiescent properties of adult HSCs. With respect to the infant
haemopoietic system (where the incidence of childhood AML is
at its highest), children up to the age of three retain features of
foetal haemopoiesis. The equivalent switch from foetal to adult
HSCs (quiescent cells) in mice occurs between 3 and 4 weeks of
age14,15. Aged HSCs and the surrounding stromal cells possess
differences in lineage output, and have altered genetic proﬁles
(e.g. inﬂammatory, DNA damage) compared to their younger
adult counterparts16,17. BM stromal cells including mesenchymal
stromal cells (MSCs), osteoblasts (OBs), and endothelial cells
(ECs) contribute to HSC function. Similar to HSCs, leukaemic
cells depend on the BM niche, and not only co-opt normal niches
but also alter them to their own advantage for propagation and
treatment survival18–20. It is not known whether changes that
occur in the leukaemic BM niche are the same in paediatric and
adult AML.
Given the large spectrum of genetic abnormalities found in
AML, there are many examples that have been shown to reca-
pitulate AML disease in the mouse, such as MLL and PML
oncofusions, and those that present pre-leukaemic features of the
disease, but not overt AML, such as AML1ETO21–23.
NUP98HOXA9 (NH9) oncogene represents 11p rearrangements
found in both paediatric and adult AML, and it has been exclu-
sively associated with myeloid leukaemia both in humans and in
experimental models. Although 11p rearrangements are rare,
NH9 is representative of deregulated HOX leukaemia, observed in
70% of all AMLs as a result of several upstream genetic alterations
that occur across all age-groups24,25. We have modelled the age
continuum using the NH9 oncogene to address how the age of
the cell of origin impacts on leukaemic disease. We show that
paediatric AML is biologically different to adult AML, and that
the age of the cell of origin signiﬁcantly inﬂuences leukaemia
latency, lineage, molecular proﬁle, and the leukaemic niche.
Results
Comparable in vitro transformation of LSKs from all ages. In
order to model the continuum of leukaemia based on the age
relationship estimated between humans and mice26, we isolated
murine lin-sca1+cKit+ (LSK) cells, which include the long- and
short-term HSCs, and myeloid progenitor populations (CMPs
and GMPs) from different ages of mice (prenatal and postnatal)
to represent infant/prenatal origins (foetal liver (FL)), childhood
(BM from 3 week(w)), young adult (10 w) and middle/old age
(>52w) C57BL/6 mice. These different aged populations were
transduced with NH9 retrovirus and assessed for in vitro trans-
formation by CFC assay. After the ﬁrst plating (P1) colonies were
enumerated and identiﬁed (Supplementary Figure 1a), and
replated up to three times (P2 and P3) (Fig. 1a). The ability of
cells to produce colonies at P3 indicates the acquisition of self-
renewal capacity and suggests in vitro transformation27. LSKs
transduced with empty vector control MigR1 did not give rise to
any colonies past P1 (Supplementary Figure 1b). Analysis of cells
from LSK-derived (P3) colonies showed no difference in the
median ﬂuorescent intensity (MFI) of GFP between the age
groups, indicating similar expression of NH9 (Fig. 1b). Expres-
sion of the NH9 fusion gene was also detected in NH9 transduced
cells from LSK-derived (P1 and P3) colonies by RT-PCR (Fig. 1c).
NH9 transduced LSKs efﬁciently produced large numbers of
colonies by P3 independent of age (Fig. 1d). However far fewer
colonies were produced by NH9 transduced FL CMPs compared
to other ages, whereas NH9 transduced FL GMPs failed to replate
to P3 (Fig. 1e, f, Supplementary Figure 1c, d). We next examined
the intrinsic transformability of foetal LSKs, CMPs and GMPs
with common AML drivers, AML1ETO and FLT3-ITD as well as
NH9. Only LSKs from FL expanded in OP9 co-culture with
different oncogenes, while FL CMPs and GMPs exhausted in
long-term culture suggesting that there is an intrinsic feature of
foetal committed myeloid progenitors that inhibits leukaemic
transformation (Supplementary Figure 1e–g). Immunopheno-
typic analysis of cells from P2 showed the absence of lymphoid
markers and expression of myeloid markers with a signiﬁcant
difference in the expression of Gr1 in FL compared to 10w and
>52W NH9 transduced LSKs (Supplementary Figure 1h). By P3
colony morphology did not differ greatly between ages of NH9
transduced LSKs. Each age population gave rise to granulocyte
erythroid macrophage megakaryocyte (GEMM), granulocyte
macrophage (GM), granulocyte (G), macrophage (M) and ery-
throid (E) colonies, although there was a signiﬁcantly higher
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proportion of mature colonies derived from >52w LSKs com-
pared with colonies derived from FL and 10w LSKs (Fig. 1g, h).
Immunophenotypic analysis showed no signiﬁcant difference in
the expression of mature myeloid (CD11b, Gr1 and F4/80) or
stem cell (cKit and CD34) markers between the ages (Fig. 1i).
These results showed that foetal transformation was restricted to
the immature LSK compartment and LSKs from all ages trans-
formed comparably in vitro.
Different leukaemia latencies due to age of cell of origin. To
investigate the inﬂuence of the BM niche on age-deﬁned LSK
homing potential, NH9-transduced P2 LSKs from each group
were transplanted into recipient mice and assessed after 18 h for
homing to different organs (Fig. 2a). NH9 transduced cells of
10W and >52W origin homed signiﬁcantly more to the BM and
spleen compared to FL and 3W NH9 transduced cells (FL vs
>52w p= 0.0000006 (BM) p= 0.02 (spleen), FL vs 10w p= 0.015
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(BM) p= 0.014 (spleen), 3w vs >52w p= 0.00003 (BM), 3w vs
10w p= 0.006 (BM) p= 0.004 (spleen). To investigate the
inﬂuence of the BM niche on age-deﬁned LSK transformability,
NH9-transduced P2 LSKs from each age group were transplanted
into recipient mice generating NH9FL, NH93W, NH910W and
NH9>52W. No signiﬁcant differences in long-term engraftment,
determined by GFP expression in PB after 16w, were observed
across the groups (Fig. 2b). Recipients were monitored for clinical
signs of leukaemia and sacriﬁced upon leukaemia development,
or after 1 year if no leukaemia had developed. Mice transplanted
with adult cells (NH910W and NH9>52W) developed leukaemia
with a signiﬁcantly shorter latency compared to young leukae-
mias (NH9FL and NH93W) (p= 0.0111) (Fig. 2c). Pooling the
results into young (NH9FL and NH93W) and adult (NH910W and
NH9>52W) revealed a 70 day increase in median survival (MS) in
the young compared to adult groups (MS 315 days vs 245 days,
respectively) (Fig. 2d). Furthermore, while 100% of mice trans-
planted with adult NH9+ LSKs developed disease, there was a
signiﬁcantly lower disease penetrance in mice receiving young
NH9+ LSKs (50–75%) (Figs. 2h, 3b). There were no age-related
differences in disease burden in leukaemic mice as assessed by
BM and spleen cellularity, and spleen weight (Fig. 2e). Similarly,
leukaemic mice from all groups displayed equivalent levels of
leukocytosis, thrombocytopenia and anaemia (Fig. 2f). There
were equivalent percentages of GFP+ cells in the PB, BM and
spleen of leukaemic mice at the time of death conﬁrming
equivalent disease burden in all groups (Fig. 2g). In addition,
there was no difference in the expression of the stem cell markers
CD34 and cKit on the leukaemic cells derived from young or
adult NH9+ LSKs (Fig. 2i). These data show that the age of the
cell of origin signiﬁcantly impacts disease latency.
Different lineage phenotypes due to age of cell of origin. We
next performed in-depth phenotypic analysis of the leukaemic
blasts by ﬂow cytometry and immunohistochemistry (IHC).
Using markers of myeloid and lymphoid leukaemia, we identiﬁed
three distinct types of acute leukaemia driven by NH9. All mice
transplanted with adult NH9+ LSKs developed AML (Fig. 3a, b)
characterised by intermediate CD11b and Gr-1 expression levels
(i.e. overt AML distinct to myeloproliferative phenotype which
was observed prior to clinical signs of AML and characterized by
CD11bhiGr-1hi expression), with low or no expression of lym-
phoid markers CD19, B220, CD4 and CD8 (Fig. 3a, c) and
positive staining for MPO by IHC (Fig. 3d). Mice transplanted
with young NH9+ LSKs developed AML but also developed two
other disease phenotypes in vivo; acute lymphoblastic leukaemia
(ALL) and mixed phenotype acute leukaemia (MPAL) (Fig. 3a, b).
The ALL disease was characterised by the absence of myeloid
markers CD11b and Gr-1, and the expression of high levels of
either CD19 or B220 on leukaemic blasts (Fig. 3a, c) as well as
positive staining for CD3 by IHC (Fig. 3d). The MPAL disease
expressed myeloid markers with low or no expression of
lymphoid markers by ﬂow cytometry (Fig. 3a, c), but positive for
both MPO and CD3 intracellularly by IHC (Fig. 3d)—an estab-
lished diagnostic criteria for MPAL28. Despite the development of
lymphoid disease in vivo, the P2 cells did not show any lymphoid
cell surface marker expression or lymphoid potential in vitro
prior to transplantation (Supplementary Figure 1h, i). When we
transplanted healthy LSKs from FL (LSKFL) and >52w BM
(LSK>52W) into 6–8w recipients we saw no age-dependent
skewing of donor cells, with both LSKFL and LSK>52w groups
having the same proportion of myeloid, B and T cells (Supple-
mentary Figure 1j, k). Therefore, the disease lineage skewing
in vivo is a result of NH9 expression speciﬁcally in young LSKs.
We characterized the three distinct disease phenotypes arising
from the young NH9+ LSKs by gene expression analysis of
lineage restricted genes. In the GFP+ leukaemic blasts from the
AML diseases there was upregulation of myeloid genes Cebpb,
Cebpe and Fcgr3 compared with ALL blasts (Fig. 3e), and lower
expression of these genes in the MPAL cells compared with the
AML cells. We observed higher expression of key B lineage genes
Cd79a, Ptprc, Pou2af1, Foxo1 and Vpreb1 in the ALL cells
compared with AML or MPAL derived cells (Fig. 3f). In addition,
expression of lymphoid genes associated with the T-cell lineage
Rag1, Rag2, Il7ra and Flt3 were also elevated in ALL blasts when
compared to AML and MPAL leukaemic cells (Fig. 3g). Together,
our in vivo results demonstrate that upon transformation the age
of the cell of origin results in biologically different diseases
suggesting that young LSKs have strong intrinsic lymphoid
programmes.
Differential regulation of the BM niche by 3w and >52w AML.
Our gene expression analysis of the three disease phenotypes
demonstrated lineage gene expression changes, but whether the
age of the cell of origin impacts the transcriptional proﬁle of the
myeloid leukaemias which developed from all age groups was
unknown. Thus, RNA-seq was performed on in vivo generated
myeloid leukaemias (NH9FL, NH93W, NH910W and NH9>52W)
(Fig. 4a). Principal component analysis (PCA) of our RNA seq
data revealed that samples clustered together according to age
(Fig. 4b). Signiﬁcant differentially expressed genes (DEGs) were
identiﬁed in pairwise comparisons between NH9FL and each age
group and ﬁltered for log fold change (LFC) of ≥1.5 and q-value
of <0.05. In this comparison, we identiﬁed 795 DEGs in NH93W
(537 upregulated in NH9FL, 258 upregulated in NH93W), 2117
DEGs in NH910W (1475 upregulated in NH9FL, 642 upregulated
in NH910W) and 1455 DEGs in NH9>52W (501 upregulated in
NH9FL, 953 upregulated in NH9>52W) (Supplementary Fig-
ure 2a). Therefore despite all samples representing GFP+ NH9-
driven myeloid leukaemic blasts, the transcriptional proﬁles were
substantially different according to the age of the cell of origin.
Overlapping those genes upregulated in NH93W, NH910W and
NH9>52W cells in comparison to NH9FL (Supplementary Fig-
ure 2b) identiﬁed a number of genes, which were uniquely
Fig. 1 LSKs from all ages display comparable in vitro transformation ability. a Schematic of CFC assay and transplantation model. Murine FL or BM cells were
isolated from mice of ages indicated. cKit enriched cells were transduced with GFP tagged NH9 virus. After 48 h the cells were sorted for GFP+ LSKs, CMPs and
GMPs and plated in methylcellulose media (M3434). Cells were replated to P3 and colonies were counted and analysed at each plating. Cells from P2 colonies
were transplanted into sub-lethally irradiated recipient mice. b Graph of cells from P3 showing no difference in the MFI of GFP with cellular age. c Gene
expression by RT-PCR of NH9 and Hprt1 (endogenous control) in NH9 (FL, 3w, 10w, >52w) or MigR1 (3w, 10w, >52w) transduced LSKs from P1 or P3 where
indicated. Graphs of the number of colonies per plate from serial replating CFC assay, produced by NH9 transduced d LSKs, e CMPs and f GMPs. g
Representative morphology of colonies at ×2 magniﬁcation from each age group at P3. Black scale bar represents 2mm. h Graph of percentage colony type
produced at P3 by NH9 transduced LSKs. GEMM Granulocyte erythroid macrophage megakaryocyte, GM Granulocyte macrophage, G granulocyte, M
macrophage and E erythroid. i Graph of surface marker expression at P3 showing no signiﬁcant differences with cellular age. b, d–f, h, i) Bars depict mean+ s.d.
Signiﬁcance determined by one-way ANOVA and Bonferroni post-test. FL n= 4, 3w n= 3, 10w n= 3, > 52w n= 3, *p < 0.05
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upregulated in each age group compared with NH9FL. These sets
of genes were analysed for gene ontology (GO) pathway enrich-
ment using the MSigDB platform. The top ten most signiﬁcantly
enriched GO pathways revealed an enriched development sig-
nature in the NH93W leukaemic cells (Supplementary Figure 2c),
enriched immune response in NH910W leukaemic cells (Supple-
mentary Figure 2d) and enrichment of cell–cell interaction
pathways in NH9>52W leukaemic cells (Supplementary Figure 2e).
The in vivo differences in disease latency and phenotype
together with the transcriptional analysis (Supplementary
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Figure 2c–e) suggests differences in niche cell interactions across
the age groups. Thus we next characterized the effect of the age of
a leukaemic cell on the BM niche by performing secondary BM
transplantations with leukaemic cells of the same phenotype
(AMLs) from NH93W and NH9>52W mice—as there was the
greatest discrimination between those groups by PCA (Fig. 4b).
Using an established ﬂow cytometry approach for identifying BM
stromal cells (Fig. 4c) we identiﬁed ECs (CD45−Ter119−CD31+),
MSCs (CD45−Ter119−CD31−CD51+ PDGFRa+) and OBs
(CD45−Ter119−CD31−CD51+PDGFRa−) in the central marrow
or compact bone (collagenase-treated bone fragments). We
assessed the disease burden of transplanted mice with >30%
GFP expression in the BM (Fig. 4d, individual mice are indicated
on the graphs in Fig. 4d–h with different symbols) by peripheral
white blood cell (WBC) counts (Fig. 4e) at the time of sacriﬁce,
and demonstrated no differences between the two cohorts. There
was a signiﬁcant increase in the percentage of ECs in the central
marrow of mice transplanted with NH9>52W cells (Fig. 4f) with
no changes in the percentage of MSCs compared to control non-
transplanted (NT) mice and mice transplanted with NH93W
leukaemic cells. There was also a signiﬁcant increase in the
percentage of MSCs and OBs in the compact bone of mice
transplanted with NH9>52W cells compared to NH93W (Fig. 4h).
These changes are speciﬁc to the leukaemic niche as the effect on
ECs, MSCs and OBs was not evident in the BM stromal cells of
mice that were transplanted with normal LSKs of foetal (LSKFL)
or >52w (LSK>52W) origin (Fig. 4g, i). There was a small decrease
in the percentage of ECs in the central marrow of mice receiving
LSK>52W compared to the LSKFL group and NT mice. No
differences in ECs, MSCs or OBs were seen in mice transplanted
with NH93W leukaemic cells (Fig. 4f, h), with their stromal
compartment similar to a NT mouse. Our data show signiﬁcant
remodelling of the BM niche in mice transplanted with adult
leukaemia cells that is not evident when the leukaemia has
developed from a young cell of origin. These data indicate that the
leukaemic niche is not the same when the leukaemia has
developed from a young or adult cell of origin.
A distinct molecular proﬁle identiﬁed for paediatric AML. The
differences in the leukaemic niche of NH93W transplanted mice
compared to NH9>52W may be explained by differential inter-
actions between the young leukaemic cells and niche cells as a
result of their intrinsic molecular proﬁle. To test this, we com-
pared the transcriptional proﬁle of the in vivo generated NH93W
and NH9>52W myeloid leukaemias. To control for genes differ-
entially expressed with normal aging, RNA-seq was performed on
LSKs of 3w (LSK3W) or >52w (LSK>52W) origin (Supplementary
Figure 3a).Comparing NH93W and NH9>52W myeloid leukaemias
using a cutoff of LFC ≥1.5 and q-value of <0.05, a total of 382
DEGs were identiﬁed (Fig. 5a)—164 upregulated in NH93W and
218 upregulated in NH9>52W leukaemic cells. Comparing LSK3W
with LSK>52W a total of 1038 DEGs were identiﬁed (Fig. 5b)—236
upregulated in LSK3W and 802 upregulated in LSK>52W leu-
kaemic cells. Only 7 genes were upregulated in both LSK3W and
NH93W DEGs, with 21 upregulated genes in common between
the LSK>52W DEGs and NH9>52W DEGs (Fig. 5c, Supplementary
Data 1, 2). All further analysis of DEGs excludes these genes so all
results indicate age-speciﬁc leukaemia changes rather than
changes due to healthy age. Our sets of DEGs (Supplementary
Data 3, 6) were then interrogated for GO pathway enrichment
using the MSigDB platform. In NH93W cells the ten most sig-
niﬁcantly enriched GO pathways included pathways related with
the immune system and response to oxygen (Fig. 5d, Supple-
mentary Data 7). There were ten genes common in ﬁve or more
of these top ten pathways (Fig. 5e), which included two innate
immune cell genes involved in toll-like receptor (TLR) signalling
—Cd180 and Ticam2. Hierarchical clustering analysis of one
hundred TLR associated genes (KEGG) revealed enrichment of
this pathway in NH93W compared to NH9>52W leukaemic cells
(Supplementary Figure 3c). In contrast, in NH9>52W leukaemic
cells compared to NH93W, the ten most signiﬁcantly enriched GO
pathways included pathways mostly related with metabolic pro-
cesses, and response to endogenous stimulus (Supplementary
Figure 3b, Supplementary Data 8). Pathways related with tissue
development and adhesion were enriched in cells of both LSK3w
and LSK>52w origin (Supplementary Figure 3d, e, Supplementary
Data 9, 10). LSK3W also showed enrichment of cell proliferation
and immune system pathways, while cell differentiation pathways
were enriched in LSK>52W.
To validate our ﬁndings that leukaemic cells of 3w and >52w
origin interact with the BM niche in different ways, a cancer-
stroma interaction database containing 628 validated
ligand–receptor interactions was used29. These include multiple
signals such as cytokine and chemokine receptors, adhesion
molecules, Notch, Wnt, and hedgehog pathways—key regulators
of HSC/LSC interactions in the BM niche. Hierarchical clustering
analysis of receptors expressed in the NH93W and NH9>52W
leukaemic cells was performed using the Stemformatics plat-
form30 (Supplementary Figure 3f). This analysis conﬁrmed
differential expression of receptors between NH93W and
NH9>52W leukaemic cells, in two-speciﬁc clusters annotated (i)
and (ii) (Supplementary Figure 3f, g). Two genes from cluster (ii)
were signiﬁcantly upregulated in NH93W leukaemic cells (Fig. 5f)
including Tnfrsf13b, a TNF receptor, found primarily on B cells,
involved in B-cell signalling and survival31. Analysis of DEGs
upregulated in NH93W myeloid blasts using STRING32 revealed a
Fig. 2 Leukaemia latencies differ with different ages of cells of origin. a Graph of percentage of cells that homed to BM, PB and spleen 18 h post transplant
of NH9 LSKFL (n= 3), LSK3w (n= 3), LSK10w (n= 3) and LSK>52w (n= 3). Signiﬁcance determined by Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. b
Percentage of GFP+ cells in PB at 16w. Graph depicts mean+ s.d. from two independent experiments. Signiﬁcance determined by one-way ANOVA and
Bonferroni post test (p= 0.44). c Kaplan–Meier survival curve of recipients transplanted with NH9 transduced LSKs from P2. Recipients censored at death.
Signiﬁcance determined by overall log rank, *p < 0.05. d Kaplan–Meier survival curve of recipients pooled into young (NH9FL and NH93W) and adult
(NH910W and NH9>52W). Recipients censored at death. Signiﬁcance determined by overall log rank, **p < 0.01. e Leukaemic burden assessed by BM and
spleen cellularity, and spleen weight. f Analysis of PB parameters of recipients with donor derived leukaemia. e, f Graphs show individual results with mean
± s.d. Red dotted lines depict normal range. Young n= 11, adult n= 15. ns not signiﬁcant as determined by Student’s t-test. g Assessment of leukaemic
inﬁltration as %GFP in BM, spleen and PB after recipient mice developed donor derived leukaemia, from young and adult groups. Young n= 10, adult n=
15. Graphs depict mean+ s.d. ns not signiﬁcant as determined by Student’s t-test. h Graph of the total number of mice from two independent experiments
developing donor-derived leukaemia in young and adult groups. i Expression of immature surface markers on GFP+ cells from BM of recipients that
succumbed to NH9 AML. Graphs show individual result with mean ± s.d. Young n= 8, adult n= 15. ns not signiﬁcant as determined by Student’s t-test. All
data representative of two independent experiments. NH9FL n= 10, NH93w n= 10, NH910w n= 5, NH9>52w n= 10, young n= 20 and adult n= 15 unless
otherwise stated
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hub of protein–protein interactions surrounding Cd180 (Fig. 5g).
These genes included innate immune cell related genes Ly86,
Cd48 and Fam26f. We next analysed the NH93W DEGs in human
AML samples using two separate datasets with either paediatric
(GSE17855, n= 237) or adult (GSE6891, n= 537) AML samples
that had been run on the same microarray platform. We
corrected for batch differences using reference genes with low
variance and mean (see Methods). From our DEG list we
identiﬁed 19 genes which were signiﬁcantly enriched in human
paediatric AML samples relative to adult AML (Fig. 5h). This
a
Adult
AMLAMLAML
n =
CD11b+
CD11b/Gr1+
Myeloid
Lymphoid
IHC
CD19+
B220+
MPO
CD3
MPAL
4 25
Young
15
71.0%
(6.3–98.4)
59.3%
(13.2–99.5)
2.1%
(0.7–3.4)
0.8%
(0.1–1.4)
53.7%
(12.8–94.6)
46.8%
(0.0–93.5)
26.3%
(5.3–71.8)
6.3%
(0–23.0)
3.7%
(0.6–5.4)
29.4%
(10.7–53.9)
76.4%
(20.9–97.8)
0%0%
26.5%
(3.4–76.7)
4.9%
(0–15.7)
0.1%
(0–0.3)
+++
–
++
+++
–
++++
++++
–
AML
100
75
P
er
ce
nt
ag
e 
of
 m
ic
e
de
ve
lo
pi
ng
 G
F
P
+
 le
uk
ae
m
ia
50
25
0
Young Old
AML
ALL
MPAL
MPAL
ALL
×60×40×40
p = 0.029*
×60 CD3MPO
b d
1.5
1.0
0.5
0.0
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
Ce
bp

Ce
bp
ε
Fc
gr
3
e 500
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
250
50
25
4
3
2
1
0
Vp
re
b1
Fo
xo
1
Po
u2
af
1
Pt
pr
c
Cd
79
a
3000
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
2000
1000
500
250
6
4
2
0
Ra
g1
Ra
g2 II7
r
FL
t3
AML
ALL
MPAL
f g
2.21 0.074
0.1797.5
93.8 0.15
0.0326.07
0.052 0.19
1.0298.7
0.59 0.094
0.01599.3
0.56 0.36
0.2398.8
8.76E-3 65.2
24.410.4
1.20 0.14
0.1298.5
0.75 0.060
0.04999.1
0 28.0
70.71.32
800
AML
600
C
ou
nt
400
200
0
800
MPAL
600
C
ou
nt
400
200
0
250ALL
200
C
ou
nt
150
100
50
0
G
r1
 P
er
C
P
-C
y5
.5
105
104
103
0 C
D
19
A
P
C
-C
y7
104
103
0
C
D
4-
A
P
C
105
Live>Single>GFP+
104
103
0
C
D
4-
A
P
C
105
104
103
0
C
D
4-
A
P
C
105
104
103
0
C
D
19
A
P
C
-C
y7
104
103
0
C
D
19
A
P
C
-C
y7
104
103
0
G
r1
 P
er
C
P
-C
y5
.5
105
104
103
0
G
r1
 P
er
C
P
-C
y5
.5
CD11b-PE
105
104
103
0
1051041030
B220 PerCP-Cy5.5
1061051041030
CD8-PE
105104103–10
3
0
GFP-FITC
1051041030
c
17.8 82.2
5.43
94.6
16.0 84.0
Fig. 3 Different leukaemia lineage phenotypes due to age of cell of origin. a Summary for the outcome for young or adult mice developing NH9+ leukaemia.
Average expression of CD11b, CD11b/Gr-1, CD19 and B220 in GFP+ BM cells is shown with expression range. For IHC ‘−‘ denotes neoplastic cells are
negative for the marker, ‘+’ denotes 20%, ‘++’ 20–40%, ‘+++’ 40–60% and ‘++++’ more than 60% positive expression in neoplastic cells. b Bar chart
of lineage of all donor derived leukaemia showing data pooled into young (NH9FL and NH93w) (n= 10) and adult (NH910w and NH9>52w) (n= 15). Graphs
depict mean+ s.d. from two independent experiments. Signiﬁcance determined by two-way ANOVA, *p < 0.05. c Representative ﬂow cytometry plots
from each disease phenotype AML (top row), MPAL (middle) and ALL (bottom). Flow cytometry plots depict CD11b, Gr-1, B220, CD19, CD8 and CD4
expression through GFP in the BM. d Representative ×40 and ×60 IHC images of sternal sections from each disease phenotype AML (top row), MPAL
(middle) and ALL (bottom). Left two columns shows MPO and right 2 columns shows CD3. Positive cells exhibit brown cytoplasmic staining. Black scale
bar represents 20 µm for ×40 images and 500 µm for ×60 images. Relative gene expression of e myeloid f B-lymphoid and g T-lymphoid genes in AML (n
= 3), MPAL (n= 4) and ALL (n= 2) generated in vivo from young LSKs transformed with NH9. Graphs depict mean LFC+ s.d
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07584-1 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5280 | https://doi.org/10.1038/s41467-018-07584-1 | www.nature.com/naturecommunications 7
100 ns
ns80
60
%
 G
F
P
 e
xp
re
ss
io
n 
in
 B
M
40
20
0
80
60
W
B
C
 c
ou
nt
 ×
10
*6
40
20
0
NH93W NH9>52WNH9>52W NH93W
NH9>52W
NH93W
NH9FL
a b
NH910W
Secondary BMT
Pathway analysis
using EGSEA
DE analysis using
voom/limma
Counts, cpm
rpkm, expression
matrices
GEO
Read mapping
using RSubread
Quality control
assessment
IIIumina
NextSeq 500
60
PCA of samples using log2 cpm
40
20
0
–20
–40
–60
–60 –40 –20 0 20 40 60 80
Stemformatics
d
CD51 PE
P
D
G
F
R
a 
P
E
-C
y7
C
D
31
 A
P
C
OB
MSC
EC
FSC-HTer119 eF450
Stroma
105
200 k150 k100 k50 k
105
104
104
103
103
–103
0
1041030
0
C
D
45
-P
er
C
P
C
y5
.5
104
103
0
105
104
103
0
c
e
30*p = 0.0133
ns
20
10
%
 M
S
C
s 
in
 s
tr
om
a
0
LSK>52WLSKFLNT
30
20
10
%
 M
S
C
s 
in
 s
tr
om
a
0
NH9>52WNH93WNT
**p = 0.005
30
20
10
%
 E
C
s 
in
 s
tr
om
a
0
LSK>52WLSKFLNT
*p = 0.032
LSK>52WLSKFL
10
8
6
4
2
%
 M
S
C
s 
in
 s
tr
om
a
0
NT
ns
25
20
10
15
%
 O
B
s 
in
 s
tr
om
a
0
5
ns
LSK>52WLSKFLNT
25
20
10
15
%
 O
B
s 
in
 s
tr
om
a
0
5
NH9>52WNH93WNT
Secondary BMT
Analysis of endosteal nicheAnalysis of central marrow
8
6
4
2
%
 M
S
C
s 
in
 s
tr
om
a
0
NH9>52WNH93WNT
ns
Secondary BMT
**p = 0.004530
20
10
%
 E
C
s 
in
 s
tr
om
a
0
NH9>52WNH93WNT
f g h i
Fig. 4 Differential regulation of the BM niche by >52w and 3w AML. a Schematic overview of RNA seq data acquisition and analysis. b Plot of principal
component analysis of gene expression in NH9FL, NH93w, NH910w and NH9>52w myeloid leukaemias, n= 3 in each group. c Flow cytometric gating
strategy used to identify endothelial cells (EC), mesenchymal cells (MSC) and osteoblasts (OB) in the stroma (CD45−Ter119−). Leukaemic burden
assessed by d%GFP in BM and e WBC count. Analysis of percentage ECs (top) and MSCs (bottom) in the stroma of central marrow of mice transplanted
with f NH9+ AML blasts or g healthy LSKs of foetal (LSKFL) or >52w (LSK>52W) origin. Analysis of percentage OBs (bottom) and MSC (top) in the stroma
of the compact bone of mice transplanted with h NH9+ AML blasts or i LSKFL or LSK>52W. d–i Graphs depict individual values with mean ± s.d. of mice
transplanted with leukaemic blasts from NH93W (n= 13) or NH9>52W (n= 9) (only mice with >30% GFP in the bone marrow are included, and individual
mice are indicated with different symbols on the graphs), and LSKFL(n= 4) or LSK>52w(n= 4) from healthy mice. NT not transplanted (n= 4). Signiﬁcance
determined by Student’s t-test, *p < 0.05, **p < 0.01
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07584-1
8 NATURE COMMUNICATIONS |          (2018) 9:5280 | https://doi.org/10.1038/s41467-018-07584-1 | www.nature.com/naturecommunications
NH93W versus NH9>52Wa b c
d e
f g
h
LSK3W versus LSK>52W
LSK3W
229 7 157
781 21 197
LSK>52W
NH93W
NH93W
NH9>52W
NH9>52W
Paediatric AML
Adult AML
NH93W
NH9>52W
8
6
4
2
0
–2
–4
–6
–8
Lo
g-
fo
ld
-c
ha
ng
e
–10
–12
8
6
4
2
0
–2
–4
–6
–8
Lo
g-
fo
ld
-c
ha
ng
e
–10
–6 –4 –2 0 2 4
Average log CPM
6 8 10 12 –4 –2 0 2 4
Average log CPM
6 8 10 12
10
8
6
*
*
*
*
*
*
* *
**
* *
*
4
Lo
g2
 (
cp
m
+
1)
2
0
10
Rgs10
Cd180 Ly86
CD48
Curated databases
Experimentally determined
Gene neighbourhood
Textmining
Co-expression
Scarb1
II10ra Pou2f2 KIk1b27
Fam26f Irf8 Emr1 Cx3cr1
8
6
4
Lo
g2
 (
cp
m
+
1)
2
0
12
10
Q
ua
nt
ile
 n
or
m
al
is
ed
ge
ne
 e
xp
re
ss
io
n
8
6
4
FA
M2
6F
FA
M2
6F
FA
M2
6F
UB
P1
RG
S1
0
ZN
F2
77
ZN
F2
77
ZN
F2
77
KL
K3
PL
EK
HM
3
ZN
F7
93
NO
TU
M
GA
M
T
EH
D4
CD
48
SN
X9
TN
S4
CL
N8
XX
YL
T1
HP
GD
FA
M
49
A
M
AG
T1
PO
U2
F2
Itg
b3
Tn
frs
f1
3b
Ed
nr
b
Cx
3c
r1
Se
rp
inf
1
Irf
8
Ti
ca
m
2
Ct
sh
Cd
18
0
Tn
fsf
12
Nc
kip
sd
Sc
ar
b1
Immune system process
Cellular response to organic substance
Response to oxygen containing compound
Positive regulation of multicellular organismal process
Regulation of neuron differentiation
Small molecule metabolic process
Regulation of nervous system development
Immune response
Cellular response to oxygen containing compound
Regulation of multicellular organismal development
Gene set name Enrichment p - value
22/1984
21/1848
18/1381
17/1395
11/554
18/1767
12/750
14/1100
12/799
17/1672
3.97e–9
6.17e–9
1.08e–8
7.57e–8
1.63e–7
4.25e–7
4.36e–7
7.06e–7
8.46e–7
9.46e–7
Fig. 5 Differential enrichment of pathways in age-deﬁned AML. MA plot highlighting signiﬁcantly DEGs from pairwise comparisons between a myeloid
leukaemia cells from NH93W and NH9>52W and b healthy LSKs of 3w (LSK3W) and >52w (LSK>52W) origin. 1 RNA sequencing experiment with n= 3
biological replicates per group. DEGs with adjusted p-value <0.05 and LFC ≥1.5 highlighted in red (up in NH9>3W) and in blue (up in NH9>52W). c Venn
diagram showing overlapping genes from LSK3W and NH93W DEGs (top) and LSK>52W and NH9>52W DEGs (bottom). d Top ten enriched GO pathways
using DEGs upregulated in NH93W compared to NH9>52W samples but not in LSK3W (157 DEGs). Analysis performed on MSigDB using C5 module (GO
Biological Processes) with an FDR q-value of <0.05. e DEGs upregulated in NH93W compared to NH9>52W but not in LSK3W, in common to 5 or more of
the top 10 pathways identiﬁed in d. f Graph of genes from cluster (ii) (See Supplementary Figure 3c, d) that are signiﬁcantly upregulated in NH93W
compared to NH9>52W. g Protein interaction network of selected proteins whose gene expression was signiﬁcantly upregulated in NH93W compared to
NH9>52W but not in LSK3W, predicted by STRING. Different types of associations between the selected proteins are represented by different line colours as
indicated in legend. Genes highlighted in bold were also identiﬁed as signiﬁcantly enriched in the human paediatric dataset in h. h Quantile normalized gene
expression of NH93W DEGs that were signiﬁcantly enriched in human paediatric AML samples (n= 237) compared to human adult AML samples (n=
537). Floating bars represent min and max values with mean. Individual probes shown, some genes with multiple probes present. Genes highlighted in bold
were also identiﬁed in STRING protein hub g
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07584-1 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5280 | https://doi.org/10.1038/s41467-018-07584-1 | www.nature.com/naturecommunications 9
paediatric AML gene signature included genes involved in
immune cell interaction FAM26F and CD48, as well as a G-
protein signalling regulator RGS10.
We next examined the expression levels of our human
paediatric gene signature within the different cytogenetic
subtypes of AML from the paediatric dataset (GSE17855, n=
237). Both FAM26F and RGS10, whose expression correlated
with poor clinical outcome, were found signiﬁcantly enriched in
AML with t(7;12) (MNX1/ETV6) and t(8;21) (RUNX1/
RUNX1T1) (Fig. 6a, b) whereas expression of CD48 did not
correlate with any AML subtype (Fig. 6c). Of the remaining
genes, the expression pattern of HPGD was strikingly similar to
that of RGS10 being signiﬁcantly higher in AML with t(7;12) and
t(8;21) (Supplementary Figure 5). To investigate the prognostic
signiﬁcance of the genes in our human paediatric AML signature
we used the OncoLnc platform to mine the available AML dataset
with prognostic information, the TCGA L-AML dataset of 150
adult AML patients. This analysis shows patients with high
expression of FAM26F or RGS10 have signiﬁcantly poorer overall
survival (Fig. 6d, e). High CD48 expression is also correlated with
poor prognosis, although this did not reach our signiﬁcance
threshold (Fig. 6f). Patients with high expression of XXYLT1 had
signiﬁcantly better overall survival than those with low expres-
sion, whereas expression levels of the remaining genes did not
signiﬁcantly impact patient prognosis (Supplementary Figure 4).
Our ﬁndings support the hypothesis that AMLs of paediatric
origin have a distinct molecular proﬁle impacting on innate
immune cell pathways, indicating differential interactions with
BM niche components compared to adult AML. Gene expression
proﬁling in AML is a well-established way to provide valuable
diagnostic insight into predicting clinical outcome and our data
show that the expression of FAM26F and RGS10, which are
signiﬁcantly enriched in two AML subtypes, correlates with
signiﬁcantly poorer clinical outcome.
Discussion
Current therapy for paediatric AML has been extrapolated from
adult AML treatment, which assumes that the disease in children
and adults are similar. The recent TARGET AML dataset showed
distinct features of age-speciﬁc AML disease, calling for increased
understanding to drive paediatric-speciﬁc therapy12. This study
provides a murine model that can recapitulate paediatric disease
features, a model that can be used to drive forward with new
modes of paediatric-speciﬁc therapies. We used an age-deﬁned
in vivo leukaemia model to address the hypothesis that the leu-
kaemia cell age inﬂuences disease biology and aggressiveness. Our
results have shown that signiﬁcant biological differences exist in
AML derived from a young or adult cell of origin. Transplanta-
tion of NH9+ adult (10w and >52w) LSKs resulted in AML in
100% of recipient mice. In contrast, transplantation of NH9+
young (FL and 3w) LSKs resulted in a less penetrant disease with
a signiﬁcantly longer latency. Whereas the self-renewal ability of
HSCs decreases with age, our model uses a bulk LSK population
that includes multipotent and more restricted progenitors with
varying self-renewal33. It is not known how the self-renewal
capacity of these cell populations changes with age. Indeed, we
observed increased homing to the BM and spleen with the older
NH9-transduced cells. Despite initial homing differences, how-
ever, similar levels of GFP (donor cell burden) were observed in
the PB after 16 weeks. It would be interesting to see whether the
age of the recipient mouse (in our case it was 6–8 wks) had an
impact on the levels of homing, engraftment and disease gener-
ated from the different age donor cells. In addition to AML, NH9
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Fig. 6 Genes in paediatric signature associate with AML subtypes and prognosis. Expression of a FAM26F, b RGS10 and c CD48 in paediatric AML patients
(GSE17855) categorised by AML subtypes—cytogenetically normal AML (CN-AML, n= 39), AML with inv16 (n= 27), MLL rearranged AML (MLL, n=
47), AML with remaining cytogenetics including t(6;9), monosomy 7, trisomy 8 and complex karyotype (RC, n= 45), AML with translocations t(15;17) (n
= 19), t(7;12) (n= 7) and t(8;21) (n= 28) and patients with unknown cytogenetics (UC, n= 25). Signiﬁcance determined by one-way ANOVA and one
sample t-test using the ggpubr package (https://CRAN.R-project.org/package= ggpubr) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. d–f
Kaplan–Meier survival analysis of overall survival of AML patients (n= 150) in the TCGA L-AML dataset with high (top quartile, n= 37) and low (bottom
quartile, n= 37) expression of d FAM26F, e RGS10 and f CD48. Signiﬁcance determined by overall log rank *p < 0.05, **p < 0.01
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drove ALL and MPAL diseases from young LSKs but not adult.
These ﬁndings are supported by observations in human leukae-
mia where lineage promiscuity has been observed more com-
monly in paediatric leukaemia34,35. Thus far the NH9 fusion
oncogene has been exclusively linked with myeloid leukaemias,
but other Nup98 fusion proteins have been identiﬁed in cases of
human paediatric T-ALL36–38. NUP98-HOXD13 can induce both
AML (60%) and T- and B-ALL in vivo39,40. The multi-lineage
disease output that we observe from a young cell of origin may be
accounted for by strong intrinsic lymphoid programmes inherent
in younger LSKs that are only revealed in the BM micro-
environment. Together our data show that the age-related tran-
scriptional landscape of cells at the time of transformation has a
signiﬁcant impact on the biology of the resultant disease.
Contrary to our in vivo results, our in vitro data showed no
difference in the lineage or transformation potential between the
different ages of NH9+ LSKs. The disparity between these models
suggested that the BM microenvironment plays a role in the age-
related differences in leukaemia observed. Upon transplantation
into secondary recipients, we observed remodeling of the BM
microenvironment by adult AML blasts (NH9>52W) with a sig-
niﬁcant increase in marrow ECs, and OBs and MSCs in the
compact bone. This correlates with several recent publications
that have identiﬁed remodelling of the BM stroma by leukaemic
blasts19,41. Leukaemic cells are protected and supported by
interacting with the BM niche, and disease relapse is caused by
the persistence of leukaemia cells that evade treatment. In
humans, adult AML patients have higher relapse rates than
children with AML. The ability of adult leukaemic cells to
remodel the BM stroma in our model suggests that speciﬁcally
targeting interactions between AML cells and the niche in adults
may improve therapy outcome and reduce the rate of relapse. In
contrast, AML blasts from NH93W mice had no effect on the
stroma of recipient mice upon transplantation. The BM niche is a
complex microenvironment consisting of multiple cell types
beyond stromal ECs, MSCs and OBS, including immune cells,
adipocytes and neural cells. Our data indicate that NH93W blasts
may interact with non-stromal elements of the niche, and eluci-
dating these interactions could identify druggable targets speciﬁc
to paediatric AML.
Hierarchical clustering analysis of genes encoding receptors
involved in cancer-stroma interactions identiﬁed enrichment of
unique gene clusters associated with either NH93W or NH9>52W
cells, conﬁrming our in vivo identiﬁcation of differential inter-
action between these age-deﬁned leukaemic blasts and the
stroma. GO pathway analysis of DEGs revealed signiﬁcant
enrichment of metabolic pathways in NH9>52W cells compared to
healthy LSK>52w, while in the young myeloid blasts (NH93W) we
observed signiﬁcant enrichment of immune system pathways, and
upregulation of genes involved in TLR signalling compared to
both healthy LSK3w and NH952w. Analysis of DEGs upregulated
in NH93W AML blasts using STRING revealed a hub of innate
immune cell interactions surrounding CD180. CD180 is a TLR-
like receptor expressed on B cells and monocytes, but not T cells,
where it forms a complex with MD-1 (Ly86) to regulate TLR2/4
LPS responses42. MD-1 was also signiﬁcantly upregulated in
NH93W myeloid blasts. Activation through CD180 mediates pro-
survival and proliferation signals in both normal and leukaemic B
cells in vitro43. CD180 has been identiﬁed as a marker of LSCs in
AML44 and along with CCR2, it was also recently identiﬁed as a
whole blood biomarker for BRD4 inhibitors 45.
Comparison of paediatric and adult AML datasets revealed a
human paediatric gene signature with 19 of the 164 murine DEGs
(11.6%) signiﬁcantly enriched in paediatric AML samples, which
included several genes involved with immune cell interaction.
Regardless of age, AML patients with high expression of 2 genes
in our paediatric signature—FAM26F and RGS10—had sig-
niﬁcantly poorer overall survival rates. RGS10 is expressed in the
brain, lymph nodes, testis and bone marrow46 where it has been
shown to play a key role in regulating inﬂammation. While little
is known about the role of RGS10 in AML, in a meta-analysis of
over 2700 AML patients across 25 published datasets RGS10 was
identiﬁed in the top 25 most common differentially regulated
genes—along with well-established AML associated genes such as
HOXA9, MEIS1 and RUNX1T147. FAM26F is a cation channel
that regulates immune response by trafﬁcking substances into or
between cells48. It has recently been proposed as an early diag-
nostic marker as its increased expression is indicative of IFN-γ
mediated immune responses49. While AML with t(7;12) is rare in
children as a whole (~3%) it is most commonly seen in infant
(0–1 years) AML with one-third bearing the translocation50. It is
a cryptic abnormality which can’t be diagnosed using traditional
karyptyping methods and is associated with very poor clinical
outcome. While t(8;21) is in fact considered a good risk AML, not
all patients in this subgroup do well and these genes may indeed
determine whether someone with t(8;21) does respond well or not
to treatment. Here we identify 2 genes, RGS10 and FAM26F
which are signiﬁcantly enriched in this subset of paediatric AML
patients which could act as a biomarker for diagnoses.
The lifetime risk of developing cancer is determined by a
combination of inherited predispositions, environmental factors,
and random mutations arising during DNA replication. While
cancer is widely considered a disease of the aged, it is the leading
cause of death in children and young adults. The appropriateness
of the current practice for some cancers of extrapolating treat-
ments across the age spectrum is dependent on the assumption
that the same aetiology underlies cancer in the young and old.
Our results show a speciﬁc transcriptional landscape of paediatric
AML that signiﬁcantly distinguishes paediatric disease biology
and is supported by murine modelling. We identify FAM26F and
RGS10 as signiﬁcantly enriched in paediatric AML associated
with the AML subtypes t(7;12) and t(8;21) and these genes are
linked with poor clinical outcome. These are potentially useful
biomarkers in paediatric AML and their function and upregula-
tion in paediatric AML of much interest. These ﬁndings underpin
the necessity to advance the development of age-appropriate and
biologically driven precision medicine for the eradication and
cure of AML in children.
Methods
Retroviral production. Plasmids were constructed in the MigR1 backbone, for the
production of retrovirus. The NUP98HOXA9-MSCV-IRES-GFP and FLT3-ITD
(N51)-MSCV-IRES-GFP vectors were a gift from Brian Huntly (Cambridge
Institute for Medical Research, University of Cambridge, UK). The AML1ETO-
MSCV-IRES-GFP vector was a gift from James Mulloy (Cincinnati Children’s
Hospital Medical Center, University of Cincinnati College of Medicine, USA).
Retrovirus was produced by calcium phosphate transfection of constructs with
packaging vectors pCGP and pHIT123 in HEK293T (ATCC) cell line. Retrovirus
containing supernatants were harvested at 24, 36 and 48 h post transfection. Viral
titres were measured by the transduction of 3T3 (ATCC) cells in the presence of
Polybrene 4 µg mL−1 (Sigma-Aldrich) and percentage of GFP determined by ﬂow
cytometry.
Retroviral transduction of primary cells. Murine BM and FL cells were retro-
virally transduced with titre-matched retrovirus to express GFP tagged oncogenes.
BM and FL cells were labelled with ckit (CD117) microbeads (Miltenyi Biotec) to
enrich cKit cells by passing through a MS Columns (Miltenyi Biotec) in the mag-
netic ﬁeld of a MACS Separator (Miltenyi Biotec). cKit enriched BM or FL cells were
pre-stimulated overnight in pre-stimulation cocktail (DMEM 15%FBS, 1 mgml−1
Penicillin/Streptomycin (PS) and 2mM L-Glu) supplemented with 10 ngml−1
recombinant murine (rm) IL3, 10 ng ml−1 rmIL6 and 100 ng ml−1 rmSCF
(Peprotech). For transduction, cells were resuspended in activation cocktail
(DMEM 15%FBS, 1 mgml−1 PS, 2 mM L-Glu, 10 ng ml−1 rmIL3, 10 ng ml−1
rmIL6 and 10 ng ml−1 rmSCF, and 4 µg ml−1 Polybrene) and virus was quickly
thawed and added. The ﬁnal cell concentration was 0.5–2 × 106 cells/mL. Two 90
min spinoculations were performed 6–12 h apart. After 48 h transduced cKit
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enriched BM or FL cells were FACs sorted for LSK, CMP and GMP populations
(see Supplementary Figure 7).
Serial colony forming cell (CFC) Assays. FACs sorted, transduced LSK, CMP
and GMP populations were resuspended in Methocult M3434 (Stem Cell Tech-
nologies). After 7–10 days, colonies were counted, categorised and images taken on
an EVOS XL Core Imaging System (Fisher Scientiﬁc). Colonies were categorised
based on their morphology as per StemCell Technology Methods and were of 4
distinct phenotypes: granulocyte erythroid macrophage megakaryocyte (GEMM),
granulocyte macrophage (GM), granulocyte (G) and macrophage (M) (Supple-
mentary Figure 1A). Cells were replated three times (P1–3).
OP9 co-culture assay. Transduced FL HSPCs (LSK, CMP and GMP) were plated
onto a sub-conﬂuent layer OP9 cells (MTA from Juan Carlos Zuniga-Pﬂucker) in
OP9 media supplemented with 10 ng µl−1 IL3, 10 ng µl−1 IL6, and 100 ng µl−1
SCF. Media were refreshed every 2 days and cells were replated to a fresh OP9 layer
every 4 days. At each replating, FL cells were counted and GFP expression
determined. If FL cells had expanded to a density of ≥1 × 106 cells per mL a 1:10
dilution was carried out. To analyze myeloid and lymphoid potential, transduced
NH9 LSK cells at P2 from FL, 3w, 10w and>52w were plated onto a sub-conﬂuent
layer OP9/ OP9-DL1 cells in OP9 media supplemented with 5 ng ml−1 Flt3 and 1
ng ml−1 IL7. Media were changed at 2 days and cells were analyzed by ﬂow
cytometry at 4 days.
BMT experiments. Donor LSKs transduced with GFP-tagged NH9 retrovirus and
expanded in methylcellulose were collected at P2. 1 × 106 GFP+ cells were intra-
venously transplanted into sub-lethally irradiated 6–8w old recipient mice
(450rads). For BM reconstitution experiments animals were monitored for
engraftment by GFP% in PB and clinical signs of leukaemia (piloerection,
tachypnoenea, reduced mobility, weight loss, PB total white cell count >20 × 106).
PB parameters were analysed on a HemaVet 950 (Drew Scientiﬁc). Animals were
killed on onset of leukaemia or 12 months post BMT. For secondary transplan-
tation, BM blasts from primary recipients that developed AML were intravenously
transplanted into sub-lethally recipient mice (B6.SJL). For homing experiments,
2 × 106 GFP NH9 transduced donor cells were labelled with CellTraceTM Violet
(CTV) (Invitrogen) and intravenously transplanted into sub-lethally irradiated
6–8w old recipient mice (550rads). Mice were killed 18 h post transplant, and BM,
PB and spleen assessed for the presence of GFP+ CTV+ donor cells by ﬂow
cytometry. Percentage of cells homed was obtained from the absolute number of
donor cells, calculated from the percentage of engraftment and total cell number
per organ, and the number of the cells injected.
Flow cytometry analysis and sorting. Peripheral blood was collected into an
EDTA lined Microvette® capillary blood tube (Sarstedt). Bones were crushed in
PBS with 2% FBS and the cells were ﬁltered through a 40 µm strainer to isolate the
central marrow. To isolate cells in the endosteal niche, the compact bone fragments
were digested with 1 mgml−1 collagenase type IV (Gibco) and 2 mgml−1 Dispase
II (Sigma) at 37 °C, twice for 15 min with agitation. Splenic and thymic cells were
ﬁltered through a 40 µm strainer. In all tissues red blood cells (RBCs) were lysed in
RBC lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). Single cell
suspensions were incubated with antibody cocktail at 4 °C for 20 min.
For myeloid staining samples were stained with CD11b PE (eBioscience 12-
0112-83) or CD11b APC (eBioscience 17-0112-83), Gr1 PerCP-Cy5.5 (eBioscience
45-5931-80) or Gr1 eFlour 450 (eBioscience 48-5931-82), F4/80 APC (eBioscience
17-4801-82), cKit ACP-Cy7 (Biolegend 105825), and CD34 biotin (eBioscience 13-
0341-82) and Streptavidin-PE-Cy7 (eBioscience 25-4317-82) at dilution 1:200.
For lymphoid staining samples were stained with CD4 APC (eBioscience 17-
0042-83), CD8a PE (eBioscience 12-0081-82), B220 PerCP-Cy5.5 (eBioscience 45-
0452-82) or B220 eFluor 450 (eBioscience 48-0452-82), CD19 APC-Fluor780
(eBioscience 47-0193-80) or CD19 APC (eBioscience 17-0193-82) and CD3e
eFluor 450 (eBioscience 48-0031-82) at dilution 1:200.
For progenitor cell isolation GFP-tagged cKit enriched BM or FL was stained
with cKit APC (eBioscience 17-1171-82), Sca1 PE-Cy7 (eBioscience 25-5981-82),
CD34 biotin and Streptavidin-PE (eBioscience 12-4317-87), CD16/32 APC-Cy7
(BD 560541) and lineage markers: eFlur®450 conjugated CD3, CD4 (eBioscience
48-0042-82), CD8a (eBioscience 48-0081-82), CD11b (eBioscience 48-0112-82)
(omitted for FL and 3w), GR1, B220 (eBioscience 48-0452-82) and Ter119
(eBioscience 48-5921-82).
For isolation of LSK cells (transplanted in control mice and for RNA-seq
analysis), BM cells were stained with lineage cocktail with the following
biotinylated antibodies: CD3 (eBioscience 13-0032-82), CD4 (eBioscience 13-0041-
85), CD8a (eBioscience 13-0081-85), B220 (eBioscience 13-0452-85), CD11b
(eBioscience 13-0112-85), Gr-1 (eBioscience 13-5931-85) and Ter119 (eBioscience
13-5921-82), followed by anti-biotin MicroBeads staining for lineage cells depletion
in LS Columns (Miltenyi Biotec) in the magnetic ﬁeld of a MACS Separator
(Miltenyi Biotec). The lineage-negative population were stained with Sca1 PE-Cy7,
cKit ACP-Cy7 and Streptavidin V450 (BD 560797) at dilution 1:200.
For identiﬁcation BM stromal cells were stained with CD45 bio (eBioscience 13-
0451-82), Streptavidin PerCP-Cy5.5 (eBioscience 45-4317-82), Ter119 eFluor 450,
CD31APC (eBioscience 17-0311-80), CD51PE (eBioscience 12-0512-82), PDGRa
PE-Cy7 (eBioscience 25-1401-80) at dilution 1:200.
Where applicable dead cells were also excluded using either a 4’,6-diamidino-2-
phenylindole (DAPI) at dilution 1:1000 (Sigma-Aldrich D9542). Flow cytometry
data were acquired using a FACSCanto II (BD Biosciences) and cells were sorted
using a BD FACSAria III (BD Biosciences). Flow cytometry data were analysed
using FlowJo software v7 (Treestar Inc).
Histopathology. Sternal sections were decalciﬁed with 5.5% EDTA solution con-
taining 10% formaldehyde for 7–8 days. Decalciﬁed sterna were embedded in
parafﬁn and sections cut at 2.5 µm and ﬁxed onto microscopy slides. Immuno-
histochemistry (IHC) was performed with anti-MPO antibody (Dako Agilent
A0398) at dilution 1:3000 or anti-CD3 (Dako Agilent A0452) antibody at dilution
1:100. Tissue sections were dewaxed in xylene and descending alcohols and
rehydrated in distilled water; endogenous peroxidase was quenched by immersion
in 3% hydrogen peroxide (H2O2) in PBS for 5 min.
Transcriptional analyses. RNA was isolated using either the RNeasy Mini kit
(Qiagen) or Arcturus PicoPure kit (Fisher Scientiﬁc) and total RNA converted to
cDNA using the High Capacity cDNA Reverse Transcription Kit (Invitrogen) as
per manufacturers’ instructions. Targeted gene expression was performed on a
48.48 dynamic array (Fluidigm) in accordance with manufactures’ protocol and
gene expression analyzed using standard techniques. For RNA sequencing, RNA
libraries were prepared by polyA selection using the TruSeq stranded mRNA kit
(Illumina). Paired end RNA-seq was performed on a NextSeq™ 500 platform
(Illumina) with a read and fragment length of 75 bp and 150 bp, respectively, to a
depth of 33 million reads. Reads were aligned using the standard Stemformatics
RNA-Seq data processing pipeline (https://www.stemformatics.org/
Stemformatics_data_methods.pdf). Differential gene expression was performed
using limma, voom and Glimma packages in R (https://f1000research.com/articles/
5-1408/v2). Signiﬁcance determined by adjusting for false discovery rate using
Benjamini-Hochberg method as used by limma. List of DEGs are provided in
supplementary data (Supplementary Data 1-2). Pathway analysis was performed
using EGSEA package in R (https://f1000research.com/articles/6-2010/v1). Raw
data are available at GEO with ID GSE107662 (AML) and GSE122066 (Normal
LSKs), and can be accessed on the Stemformatics platform at https://www.
stemformatics.org/datasets/search?ds_id=7127# and https://www.stemformatics.
org/datasets/search?ds_id=7311#.
Gene lists of DEGs were interrogated for GO pathway enrichment using the
Molecular Signatures Database (MSigDB) (Broad Institute)51. Overlaps were
computed with a false discovery rate (FDR) q-value below 0.05 using the C5 GO
module. Where indicated, analysis was carried out using Stemformatics data
analysis platform30. When analyzing GSE17855 and GSE6891 standard batch
correcting methods sva52 and ruv53 over-or-under corrected the data. Instead an
alternative approach was used. A set of reference genes common to both datasets,
with low variance and mean within each datasets were identiﬁed and used for
normalization. First the datasets were quantile normalised so that their value
ranges were compatible, and the probes with low variance and mean were
identiﬁed to be used as the reference genes. The 164 DEGs upregulated in NH93W
compared to NH9>52W were then mapped to their human orthologues and
corresponding probe identiﬁers in each dataset. Comparing the difference between
each probe and the reference probe identiﬁed genes signiﬁcantly enriched in the
human paediatric AML dataset (where the p-value is the result of the t-test for the
null hypothesis where the means of these differences are equal).
Prognostic signiﬁcance was determined using the OncoLnc platform (http://
www.oncolnc.org/) which links to TCGA survival data54. Selected genes were
analysed within the L-AML dataset of 150 AML patients. Patients were ﬁltered for
high (top quartile, n= 37) or low (bottom quartile, n= 37) expression of each
gene. AML subtype graphs were generated using ggplot2 package in R (http://www.
R-project.org/). For multiple groups comparison one-way ANOVA and t-test were
calculated using the ggpubr package in R and each of the genes’ mean expression
was compared to the base-mean of the rest.
RT-PCR analysis. RNA was extracted from P1 and P3 NH9 and P1 MigR1 cells
from different ages using the RNeasy® Mini kit (Qiagen). Reverse Transcriptase
PCR was performed following the protocol from High Capacity cDNA Reverse
Transcription Kit. Primer names and sequences provided in Supplementary
Table 1 and uncropped gels provided in Supplementary Fig. 6, in Supplementary
Information ﬁle.
Quantiﬁcation and statistical analysis. GraphPad Prism v7 (GraphPad Software
Inc.) was used for statistical analysis and production of graphs. When 2 groups
were compared and F-test was performed to determine sample variance, then an
unpaired, two-tailed Student’s t-test was used to determine signiﬁcance. When
more than 2 groups with 1 variable were compared, a one-way ANOVA with
Bonferroni post-test for FDR was used to determine signiﬁcance. When more than
2 groups with two variables were compared, a two-way ANOVA with Bonferroni
post-test for FDR was used to determine signiﬁcance. For comparison of survival
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curves the Log-rank test was used. Signiﬁcance was attained with a p-value (or
adjusted p-value for FDR) of <0.5 (*), <0.01 (**), <0.001 (***) and <0.0001 (****).
Animals and ethical compliance. C57BL/6 (CD45.2+, B6) mice were purchased
from Charles River UK. B6.SJL-Ptprca/BoyAiTac (CD45.1+, B6.SJL) mice bred
and housed in the Beatson Biological Service and Research Units. All animal
experiments have been carried out at the University of Glasgow and were approved
by United Kingdom (UK) Animal Ethical Committees and performed according to
UK Home Ofﬁce project license 60/4512 (Animal Scientiﬁc Procedures Act 1986)
guidelines.
Data availability
There are no restrictions on data availability. The RNA-Seq data containing
NH9 samples are available at Stemformatics dataset [7127]. The raw data have been
deposited in NCBI’s Gene Expression Omnibus (GEO), with accession number
[GSE107662]. The RNA-Seq data containing wild-type LSK samples are available at
Stemformatics (dataset [7311]), and the raw data have been deposited in GEO with
accession number [GSE122066]. These raw data are associated with Figs. 4a, b,
5a–h Supplementary ﬁgures 2a–e, and 3a–g.
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